We also demonstrated that a combination of CAR-T therapy with LB-100 increased PD-L1 expression on tumor cells, which suggests that the checkpoint mechanisms to suppress adaptive immune responses are still present, and that combination with checkpoint inhibitors may improve therapeutic efficacy. This evidence concerns the gene CD274 and neoplasm.